1-2 of 2
Valerie de Haas
Close
Sort by
Journal Articles

Clofarabine added to intensive treatment in adult patients with newly diagnosed ALL: the HOVON-100 trial

Clinical Trials & Observations
Anita W. Rijneveld, Bronno van der Holt, Okke de Weerdt, Bart J. Biemond, Arjen A. van de Loosdrecht, Lotte E. van der Wagen, Mar Bellido, Michel van Gelder, Walter J. F. M. van der Velden, Dominik Selleslag, Daniëlle van Lammeren-Venema, Constantijn J. M. Halkes, Rob Fijnheer, Violaine Havelange, Geerte L. van Sluis, Marie-Cecile Legdeur, Dries Deeren, Alain Gadisseur, Harm A. M. Sinnige, Dimitri A. Breems, Aurélie Jaspers, Ollivier Legrand, Wim E. Terpstra, Rinske S. Boersma, Dominiek Mazure, Agnes Triffet, Lidwine W. Tick, Karolien Beel, Johan A. Maertens, H. Berna Beverloo, Marleen Bakkus, Christa H. E. Homburg, Valerie de Haas, Vincent H. J. van der Velden, Jan J. Cornelissen, the Dutch-Belgian HOVON Cooperative group
Journal: Blood Advances
Blood Adv (2022) 6 (4): 1115–1125.
https://doi.org/10.1182/bloodadvances.2021005624
Published: 2022
Includes: Supplemental data
Journal Articles

Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome: TMD Prevention 2007 study

Clinical Trials & Observations
Marius Flasinski, Kira Scheibke, Martin Zimmermann, Ursula Creutzig, Katarina Reinhardt, Femke Verwer, Valerie de Haas, Vincent H. J. van der Velden, Christine von Neuhoff, C. Michel Zwaan, Dirk Reinhardt, Jan-Henning Klusmann
Journal: Blood Advances
Blood Adv (2018) 2 (13): 1532–1540.
https://doi.org/10.1182/bloodadvances.2018018945
Published: 2018
Includes: Supplemental data